Initial observations were conducted at low magnification, followed by the selection of specific regions of interest for high-resolution imaging and detailed structural analysis
Known as GLP-1 drugs, these pharmaceuticals are primarily meant to help people with diabetes control their blood sugar levels, but have the side effect of promoting weight loss and breaking down fat and sugar in the body
According to Novo Nordisk, the manufacturer of Wegovy, the shortage is expected to continue through 2024 and affects the following dose strengths: 0.25 mg (taken during month one) 0.5 mg (taken during month two) 1.0 mg (taken during month three) On the other hand, it is anticipated that the 1.7-milligram and 2.4-milligram strengths, taken during months four and five, respectively, are likely to be unaffected
The successful implementation of GLP-1-based therapies could lead to decreased hospitalization rates, lower healthcare costs, and improved quality of life for patients